TLV Partners

TLV Partners is one of the most established early-stage firms in Israel, and its healthcare investing fits inside a broader thesis about technical Israeli founders building category-defining global software companies. The firm writes $1M-$5M checks across pre-seed, seed, and Series A and operates from Tel Aviv with the kind of relationship density across Israeli technical talent that has shaped Israeli venture for years. Founders pitching TLV should expect a conversation grounded in technology and ambition rather than in vertical specialization.

The declared sub-verticals are AI/ML in healthcare and health IT software, with a strong AI focus. In practice that means interest in clinical AI, healthcare data infrastructure, machine learning applied to medical imaging and diagnostics, software for providers and payers, and AI-enabled tooling for life-sciences operators. The firm is generally less active in therapeutics, in consumer wellness without technical depth, or in regional plays that lack global ambition. The strongest fits are technically deep Israeli companies building global software products that happen to address healthcare problems rather than Israeli companies focused only on the domestic market.

Check sizes of $1M-$5M position the firm as a lead or co-lead on early-stage rounds in Israel, often anchoring the syndicate that subsequent international investors join. Geographically the focus is Israel with active engagement on cross-border rounds, and the firm is part of the small group of Israeli VCs that consistently lead seed rounds for technically ambitious companies. The team has long-running relationships with US and European follow-on investors who participate in Series A and beyond, which matters for Israeli founders building toward international scale from day one.

The team is built around senior investors with operator, technology, and venture backgrounds. Diligence tends to be sharp on the technical thesis and the path to global scale, with detailed conversations about the underlying engineering, the realistic shape of a US or European go-to-market motion, and the credibility of the team’s ability to execute internationally from an Israeli base. Founders should expect direct engagement and a strong bias toward speed once conviction is established.

For founders, the practical read is that TLV is a credible early-stage partner for technically deep Israeli healthcare AI and IT software companies with global ambition. It is less useful for therapeutics, for consumer-only plays, or for founders who do not have a credible international thesis. The engagement style is hands-on and ambitious, with partners who tend to push companies toward bigger scope and faster execution rather than smaller, safer plays. Founders building healthcare AI software in Israel and looking for a domestic anchor that can lead the early round and stay through Series A while pulling in international syndicates will find TLV one of the most credible options in the Israeli ecosystem.